Erysipelas is known as a human infectious disease, which, unfortunately, in recent years has not reduced its incidence rate in spite of all the advances of medicine. There is a tendency to an increase in the incidence of complicated forms of erysipelas, the consequences of which require prolonged conservative treatment and expenses. Moreover, there is a transition to recurrent forms often associated with large-scale surgical interventions and sometimes plastic surgeries to close skin defects. Thus, the search for best options for treating erysipelas, preventing its recurrence or transition to more severe clinical forms is an urgent issue that requires research aimed at improving the integrated treatment of this pathology. One of the solutions to this problem is the use of bacteriophages in combination with the standard treatment of erysipelas. The aim of the study was to improve the clinical results of erysipelas complex treatment by adding local bacteriophage therapy. Our clinical study included 28 patients with erythematous and erythematous-bullous forms of erysipelas. Two groups of patients were made up to compare the efficacy of the combined use of bacteriophages and standard antibacterial therapy. Evaluation of the efficacy was performed by clinical and microbiological methods. Based on the results of clinical study, we have found out that topical use of bacteriophages incorporated into dressing material in the course of erysipelas treatment, in addition to standard antibacterial therapy and detoxification leads to a statistically significant decrease in the duration of hyperthermic reactions in patients by 0.6 ± 0.13 days, lowering in intensity and the duration of pain syndrome by 0.9 ± 0.21 days, a more rapid local swelling fading by 0.5 ± 0.3 days, enhanced decrease in local skin hyperemia by 27% and accelerated microbial decontamination in the lesion areas by 21%. The results obtained allow us to recommend applying local bacteriophage treatment as a part of the standard management of erysipelas to promote the healing period and to improve the clinical condition of patients.